RGCC Testing: Powerful Tools for Precision Cancer Detection and Personalized Treatment
In the field of modern oncology, early detection and personalized treatment have become key to improving survival rates and quality of life for patients. RGCC (Research Genetic Cancer Centre) testing is a series of advanced blood-based assays that require only a single blood draw to analyze circulating tumor cells (CTCs) and related biomarkers. These tests provide critical insights into the presence, progression, and treatment response of cancer, helping physicians create truly tailored treatment plans. The three most commonly used tests—Oncotrace, Onco-D-clare, and Onconomics Plus—excel in monitoring, screening, and treatment optimization, respectively.
What is RGCC Testing?
At the heart of RGCC testing is the isolation and in-depth analysis of circulating tumor cells (CTCs) from peripheral blood. These cancer cells, which detach from the primary tumor and enter the bloodstream, offer a real-time snapshot of tumor behavior. Compared to traditional tissue biopsies or imaging, RGCC tests are non-invasive, repeatable, and highly informative—making them ideal for early screening, treatment monitoring, and relapse detection.
Overview of the Three Core Tests
Oncotrace: Real-Time Tumor Dynamics Monitoring
Accurately detects and quantifies circulating tumor cells to assess current tumor burden, metastasis risk, and treatment effectiveness. Particularly suitable for patients during treatment, post-treatment follow-up, or in remission.
Onco-D-clare: Early Cancer Risk Screening
Identifies potential cancer risk through gene expression patterns before any visible tumor forms, with a clinical accuracy of approximately 93%. Ideal for individuals with family history, long-term concerns, or those seeking regular health monitoring. Results are available in as little as 7–10 days.
Onconomics Plus: Personalized Drug Sensitivity Testing
Directly tests the patient’s own tumor cells for sensitivity to over 90 chemotherapy agents, 60+ targeted therapies, 50+ natural substances, as well as immunotherapy, hyperthermia, and radiotherapy responses—helping physicians avoid ineffective drugs, minimize side effects, and identify the most potent treatment combinations.
Why Choose RGCC Testing?
- Detects potential risks earlier than conventional methods
- Enables true “one patient, one plan” precision medicine
- Non-invasive and repeatable, allowing ongoing monitoring of disease changes
- Integrates conventional drugs with natural therapies for more comprehensive options
- Extensive clinical data shows that declining CTC counts often indicate effective treatment and better prognosis
More Specialized Tests Await Exploration
Beyond the three most popular options—Oncotrace, Onco-D-clare, and Onconomics Plus—RGCC offers a range of advanced tests, such as Oncocount (simple CTC counting for relapse tracking), Metastat (metastasis risk assessment), and Immune Frame (immunotherapy readiness evaluation). The most suitable combination varies depending on each patient’s stage and needs.
Feel free to contact us at any time. Our professional medical team will explain each option in detail and recommend the RGCC testing plan best suited to your specific situation. The sooner you understand your tumor dynamics, the more precisely you can fight cancer—let us take that important step together for your health.
Disclaimer：
The information provided in this article is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, nor should it replace professional medical advice. Readers are encouraged to consult with a qualified healthcare provider or integrative oncology specialist before making any changes to their diet, treatment plan, or lifestyle based on the content herein. Therapies and tests mentioned, including immune or integrative treatments, should always be…
All product names, test references, and therapy mentions are for informational context only and do not constitute endorsement. Results and experiences may vary among individuals.